A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC)

Authors:
  • MNMakoto Nishio
    Makoto Nishio
  • NYNoboru Yamamoto
    Noboru Yamamoto
  • KCKenichi Chikamori
    Kenichi Chikamori
  • THToyoaki Hida
    Toyoaki Hida
  • MMMakoto Maemondo
    Makoto Maemondo
  • NKNobuyuki Katakami
    Nobuyuki Katakami
  • TKToshiyuki Kozuki
    Toshiyuki Kozuki
  • HYHiroshige Yoshioka
    Hiroshige Yoshioka
  • TSTakashi Seto
    Takashi Seto
  • TFTamaki Fukuyama
    Tamaki Fukuyama
  • TTTomohide Tamura
    Tomohide Tamura

Abstract
No abstract available

This publication has 11 references indexed in Scilit: